Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy
and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large
B-cell Lymphoma (DLBCL)
What is the impact of stem cell dose on outcome after autologous transplant?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
Following enrollment, patients will be CD34+ stem cell mobilized with plerixafor,
at the discretion of the treating attending physician, for the achievement of >6 x10^6
CD34+ cells/kg. The patients that fail to mobilize >6 x10^6 CD34+ cells/kg will not
be randomized and will subsequently be followed for disease progression and overall
Patients with >6 x10^6 CD34+ cells/kg cryopreserved on study will be admitted to the
hospital for planned autologous stem cell transplant (ASCT). Patients will be randomly
infused with either 3-4 x 10^6 CD34+ stem cells/kg or 6-8 x10^6 CD34+ stem cells/kg.
Patients will receive standard supportive measures (including: growth factor support
post-HDT/ASCT, antimicrobial prophylaxis, red blood cell and platelet transfusion
and treatment for neutropenic fever) as per institutional guidelines.
Study Reference #: UBMT-16009
Lead Researcher (Principal Investigator)
Michael Becker, MD
Study Contact InformationStudy Coordinator: katherine Nedrow
Phone: (585) 275-3893
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search